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Abstract Up to 7% of Caucasians may demonstrate ultrarapid assays for the CYP2D6*3, CYP2D6*4, CYP2D6*5, CY- 
metabolism of debrisoquine due to inheritance of alleles with P2D6*6 and CYP2D6*7 null alleles [4--11]. 
duplicated functional CYP2D6 genes. Here we describe the Up to 7% of Caucasians are ultrarapid metabolizers (UMs) 
genomic organization of the duplicated CYP2D6 genes in the 42 of debrisoquine due to inheritance of alleles with duplication 
kbXbalallele. We postulate that this duplication originates from of functional CYP2D6 genes [12-14]. The mechanism by 
a homologous, unequal cross-over event which involved two 29 kb which this duplication has occurred is not known. When sub- 
XbaI wild-type alleles, and had break points within a 2.8 kb jected to standard doses of CYP2D6 substrates, UMs may 
direct repeat (CYP-REP) flanking the CYP2D6 gene. More- suffer from therapeutic failure because of the very rapid meta- 
over, we have designed two different PCR assays for detection of bolic conversion of the drugs [15,16]. Phenotyping with probe 
alleles with duplicated CYP2D6 genes. Both assays correctly drugs may be used to identify both PM and UM subjects. 
identified 29 out of 29 subjects positive for the 42 kb XbaI allele. However, the procedure is time-consuming and expensive, 
No false negative or false positive reactions were observed, and phenotype determination can b~ confounded by concomi- 
Key words: CYP2D6 genotyping; Debrisoquine tant use of other drugs which afffct CYP2D6 activity. 
4-hydroxylase; Gene duplication; Long-PCR; Restriction fragment length polymorphism (RFLP) analysis 
Ultrarapid metabolizer after digestion with XbaI has been a widely used method to 
describe different CYP2D alleles. The three most frequent 
XbaI fragments are 29, 44 and 13 kb (11.5 kb), respectively 
[17]. The common 29 kb allele contains the CYP2D6 gene 
1. Introduction (wild-type or mutant) and the two pseudogenes CYP2D8 
and CYP2D7 [18]. The 44 kb XbaI allele is usually associated 
The cytochrome P450 enzyme debrisoquine 4-hydroxylase, with the CYP2D6*4 mutation, and comprises the CYP2D6 
encoded by the CYP2D6 gene on chromosome 22, metabo- gene and the three pseudogenes CYP2D8, CYP2D7AP and 
lizes many different classes of commonly used drugs such as CYP2D7BP [19]. The 13 kb CYP2D6*5 allele is generated 
antidepressants, neuroleptics and cardiovascular agents [1]. by a deletion of the entire CYP2D6 gene, and contains only 
CYP2D6 enzyme activity can be measured in vivo after oral the pseudogenes CYP2D8 and CYP2D7 [6,20]. In addition, a 
intake of a single dose of the probe drugs debrisoquine or 42 kb XbaI allele with two copies of the CYP2D6 gene as well 
sparteine with subsequent determination of the ratio between as one copy of each of the pseudogenes CYP2D8 and 
the urinary recovery of the drug and the metabolite. In Cau- CYP2D7 has been described [12-14]. The duplicated 
casian populations, there is a large variation in the metabolic CYP2D6 genes are usually functional, and the 42 kb allele 
ratio (MR) of the probe drugs, leading to the classification of has therefore been associated with the UM phenotype. 
three different phenotypes: poor, extensive and ultrarapid me- We have recently demonstrated the presence of two large 
tabolizers, direct repeats (CYP-REP) flanking the CYP2D6 locus [11,20]. 
5-10% of Caucasians are classified as poor metabolizers The break points of the CYP2D6*5 gene deletion allele are 
(PMs) of debrisoquine due to inheritance of two mutant present within the 2.8 kb CYP-REP regions, indicating that 
CYP2D6 null alleles [2,3]. With some CYP2D6 drug sub- the deletion has occurred by homologous, unequal recombi- 
strates, PM subjects may develop toxic plasma concentrations nation [20]. We also proposed that alleles with duplication of 
and adverse reactions at the standard recommended dose due CYP2D6 could be explained as a reciprocal of the deletion 
to impaired metabolism. Most of the non-functional CYP2D6 event, involving the same CYP-REP units. 
alleles have been described and characterized, and more than Here we characterize the UM-related alleles with CYP2D6 
95% of PM subjects can easily be detected by the use of PCR duplication, and describe different specific and reliable PCR 
assays which can be used to identify UM subjects. 
*Corresponding author. Fax: (47) (55) 97 51 41. 
2. Materials and methods 
Abbreviations." CYP, cytochrome P450; MR, metabolic ratio; PM, 
poor metabolizer; RFLP, restriction fragment length polymorphism; 2.1. Nomenclature 
UM, ultrarapid metabolizer. Throughout this report we use the new recommended nomenclature 
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[21] for the different human CYP2D6 alleles, e.g. CYP2D6*I (instead HindIII, KpnI and XbaI (New England Biolabs Inc., Beverly, MA, 
of CYP2D6wt), CYP2D6*2 (CYP2D6L), CYP2D6*3 (CYP2D6A), USA) according to the manufacturer's instructions. The digests were 
CYP2D6*4 (CYP2D6B), CYP2D6*5 (CYP2D6D), CYP2D6*6 analysed by eleetrophoresis in an ethidium bromide-containing 1% 
(CYP2D673, CYP2D6*7 (CYP2D6E) and CYP2D6* 16 (CYP2D6D2). agarose gel. 
2.2. Subjects 2.6. Automatic DNA sequencing 
The samples used in this study were from individuals of Caucasian, The cyp-205/cyp-42 PCR product was purified with a Qiagen PCR 
black American and North African origin and have been described in purification kit (Qiagen Inc., Chatsworth, CA, USA) and the 5'- and 
more detail previously [5,22]. Y-ends of the CYP-REP-DUP unit were sequenced with the primers 
cyp-12, 5'-CTAGGGTTGGAGCCAAACAAGTGTC and cyp-30, 5'- 
2.3. Debrisoquine phenotyping and CYP2D6 genotyp ing  CTCCCTGGGAGCTAGCAGAC-3'. The AmpliTaq FS Dye Termi- 
Debrisoquine phenotyping was carried out as described previously nator Cycle Sequencing Kit (Applied Biosystems Inc., Foster City, 
[5]. DNA was isolated by standard procedures from leukocytes CA, USA) was applied according to the manufacturer's instructions, 
(EDTA-anticoagulated blood). The subjects had previously been gen- and all reactions were analyzed on an ABI 373A DNA Sequencer. 
otyped by Xbal RFLP analysis to detect he different CYP2D6 Xbal 
alleles and by PCR methods to determine the PM-associated CYP2D6 
mutations CYP2D6*3, CYP2D6*4 and CYP2D6*5 and, in some cases 3. Results and discussion 
CYP2D6*6 and CYP2D6*7 [5,10,11,23]. The presence of the 42 kb 
XbaI allele was confirmed by RFLP analysis with EcoRI. The CY- 
P2D6*2 allele was identified by a modified PCR-based restriction 3.1. PCR amplification and genomic characterization of the 
digestion assay as described previously [24]. duplicated CYP2D6 genes 
We have recently demonstrated the presence of large, direct 
2.4. Long-PCR-based methods repeats flanking the CYP2D6 gene: a 3.4 kb sequence posi- 
All experiments were performed with standard thick-walled PCR tioned immediately downstream of CYP2D6 also occurs 
tubes (GeneArnp PCR reaction tubes, Perkin Elmer, Foster City, 
CA, USA) on a Perkin Elmer DNA Thermal Cycler (model TC1 or downstream of CYP2D7 [11,20]. However, in the latter case, 
480) using the GeneAmp XL PCR kit (Perkin Elmer) which contains a 1.6 kb DNA element has been inserted, so that the 3.4 kb 
rTth DNA polymerase in combination with VentR DNA polymerase, sequence splits into 0.6 and 2.8 kb repeats [20] (Fig. 1). The 
The 3.3XXL PCR reaction buffer (supplied by Perkin Elmer) con- 2.8 kb unit, termed CYP-REP, contains an Alu element and a 
tained Tricine, K(OAc), glycerol and DMSO (exact concentrations 
tandem 10 bp direct repeat, sequences postulated to be hot- not given by the manufacturer). PCR were performed according to 
the manufacturer's instructions in 100 gl reaction volumes containing spots for recombination events [20]. We also demonstrated 
lxXLPCRreactionbuffer,  500nggenomicDNA, 200 gM of each that the CYP-REP units downstream of CYP2D7 and 
dNTP, 0.3 BM of each primer and 2 U of rTthlVenta DNA polymer- C YP2D6, referred to as CYP-REP-7 and CYP-REP-6, respec- 
ase. The following primers were used: cyp-17 (forward), 5'- tively, have been involved in the generation of the CYP2D6*5 
TCCCCCACTGACCCAACTCT-3'; cyp-32 (reverse), 5'-CACGTG- 
CAGGGCACCTAGAT-3'; cyp-42 (reverse), 5'-CCGGATTCCAGC- deletion allele, since the break points for this large gene dele- 
TGGGAAATG-3'; cyp-205 (forward), 5'-CCCAGCCACCATGGT- tion are present within the repeated 2.8 kb regions [20]. 
GTCTTT-3' and cyp-207 (forward), 5'-CCCTCAGCCTCGTC- Based on these findings, we decided to study the UM-re- 
ACCTCAC-3'. The conditions for amplification with the primer pairs lated 42 kb XbaI alleles with duplicated CYP2D6 genes. Most 
cyp-205/cyp-42, cyp-207/cyp-32 and cyp-17/cyp-32 were as follows: an 
initial denaturing step of 93°C for 1 min, followed by 30-35 cycles of likely, the mechanism of duplication has involved homolo- 
93°C for 1 min, 67°C for 30 s and 68°C for 2-12 min, and a final gous, unequal cross-over, and either the 0.6 or 2.8 kb direct 
elongation step of 72°C for 10 rain. The resulting PCR products were repeats flanking the CYP2D6 gene could be implicated in this 
separated and detected in ethidium bromide-containing 1% agarose process. Depending on which repeat was involved in the cross- 
gels. over event, different CYP2D XbaI RFLP alleles would be 
2.5. Restriction enzyme analysis generated. The two possible recombinations are illustrated 
The cyp-205/cyp-42 PCR product was digested with BamHI, EcoRI, in Fig. 1. A sequence starting from any position within the 
A B 
29 kb XbaI allele 0..6 , 2.8 , , 3.4 , 29 kb Xbal allele 0.~ , 2.8 , , 3.4 
n n 
29 kb Xbal allele ~ 29 kb Xbal allele j 
Deletion allele Deletion allele 
n nm 
Duplication allele I 13.7 kb cross-over unit I Duplication allele 112.1 kb crossover unitl 
7 ~ 7 6 
Fig. 1. Postulated mechanisms for generation of alleles with duplicated CYP2D6 genes. The panels show homologous, unequal cross-over in 
either the 0.6 kb (A) or 2.8 kb (B) direct repeats flanking the CYP2D6 gene. 
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l 2 3 4 5 6 7 8 RFLP analysis. On the basis of currently available informa- 
tion, the scheme shown in Fig. 1B appears the more likely 
since a 12.1 kb fragment has been observed by EcoRI 
RFLP analysis in individuals with the 42 kb XbaI allele [12- 
Z3.] kb--P.- 14]. 
9.4 kb-.,~ To investigate further the mechanism by which the duplica- 6.6 kb~ 
4.4 kb.--I~ tion occurred, we decided to amplify and characterize the 
unique CYP2D6-CYP2D6 intergenic region of the tandemly 
2.3k!~-~ arranged genes in the duplication alleles. Two CYP2D6-spe- 
2.0 ~ cific primers, one forward primer in exon 9 (cyp-205) and one 
reverse primer in intron 2 (cyp-42), amplified a 9.3 kb frag- 
"91--1353 bp ment only in subjects with the 42 kb XbaI allele (Figs. 2 and 
• ~-1078 bp 3). Using these primers, a PCR fragment of 10.9 kb, which 
872 bp would be expected for alleles generated by unequal cross-over 
involving the 0.6 kb repeats (Fig. 1A), was not detected. 
603 bp Moreover, restriction digestion of the 9.3 kb PCR product 
with BamHI, EcoRI, HindlII, KpnI and XbaI yielded frag- 
Fig. 2. PeR amplification and restriction enzyme digestion of the 
CYP2D6-CYP2D6 intergenic region of a 42 kb XbaI allele. The ments with sizes as expected from an allele with break points 
primer pair cyp-205/cyp-42 amplified a 9.3 kb PeR product (lane 2) in the CYP-REP units (Fig. 2 Fig. 3). These results strongly 
from the intergenic region between the duplicated genes in a 42 kb indicated that the CYP2D6 duplication allele had been gener- 
XbaI allele. Digests of the 9.3 kb fragment by BamHI, EcoRI, ated by homologous unequal cross-over involving the 2.8 kb 
HindlII, KpnI and Xbal are shown in lanes 3-7, respectively. The CYP-REP units, and not the 0.6 kb repeats. 
sizes of the DNA markers )dHindlII (lane 1) and ~X-174/HaelII 
(lane 8) are indicated. The CYP-REP-7 and CYP-REP-6 units are almost identical 
except for four basepairs in the 5'-end and four basepairs in 
the 3'-end [20] (Fig. 3). According to the mechanism described 
0.6 kb repeat downstream of CYP2D7 and extending to the in Fig. 1B, it could be expected that the CYP-REP repeat 
corresponding position in the homologous repeat downstream located in the CYP2D6-CYP2D6 intergenic region (CYP- 
of CYP2D6 comprises 13.7 kb. A homologous, unequal cross- REP-DUP) would be a hybrid of CYP-REP-6 in the 5'-end 
over between two wild-type CYP2D alleles (29 kb XbaI) in- and CYP-REP-7 in the 3'-end. The 9.3 kb cyp-205/cyp-42 
volving the 0.6 kb repeats would therefore produce a deletion PeR product was subjected to sequencing of the 5'- and 
allele and a CYP2D6 duplication allele with a 13.7 kb extra Y-ends of the CYP-REP-DUP unit. The DNA sequence 
fragment when subjected to EcoRI RFLP analysis (Fig. 1A). was identical for the 42 kb CYP2D6*I and CYP2D6*2 alleles, 
The alternative recombination i volves a fragment spanning and demonstrated that CYP-REP-DUP is identical to CYP- 
the 12.1 kb region between the two 2.8 kb repeats. A homo- REP-6 and CYP-REP-7 in its 5'- and 3'-ends, respectively 
logous, unequal cross-over event between two 29 kb XbaI (Fig. 3). The CYP-REP-DUP unit is therefore a reciprocal 
alleles affecting these regions would generate the 13 kb (11.5 of the CYP-REP-DEL repeat of the CYP2D6*5 gene deletion 
kb) CYP2D6*5 deletion allele and a reciprocal CYP2D6 du- allele (Fig. 1B), as we previously hypothesized [20]. These data 
plication allele (Fig. 1B). The postulated uplication allele confirm that the duplication of the CYP2D6 gene has oc- 
should yield an additional 12.1 kb fragment upon EcoRI curred by homologous, unequal cross-over involving the 2.8 
H K K H K H 
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1 7> 5,2 <32 1 7> 3,6 <32 17> 
lkb <32 207> 3,2--------<32 Z07> 
<42 205> 9,3 <42 20S> 
CYP-REP-7 - -  CYP-REP-DUP CYP-REP-6 
B:  Barn HI / /  
E: HCO RI 5' 14 28 2670 15 11 I 3' 
H: H ind  II I  CYP-REP-6  cagcctcgtc  acct . . c ta . . tacag  .... gc t . . cgcatc . .gcc tgg  tcaacaagag 
i i /1111/11  i i i i  i i i  i i i i /  i i i i i  i / i i / i  i i i /  
K :  F~D I CYP-REP-DUP cagcctcgtc  acc t . . c ta . . tacag  . . . .  g t t . . cacacc . .g tc tgg  g tgataagta  
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X: Xba  I CYP-REP-7  acacctc tca  acct . . cca . . tc tgg  .... g t t . . cacacc . .g tc tgg Jg tgataagta  
Fig. 3. Oenomic organization of the 42 kb CYP2D XbaI allele. The 42 kb allele is aligned with respect to restriction maps and sequence simi- 
larity according to our present results. The shaded area indicates the 'extra' CYP2D6 sequence, as compared to a 29 kb XbaI allele. Large 
boxes are CYP2D genes and pseudogenes, and smaller boxes represent the 0.6 and 2.8 kb direct repeats. The horizontal arrowheads indicate 
binding sites for the different upper and lower primers. Arrowheads connected by lines show PeR products which were amplified by the prim- 
ers. Underneath, nucleotide sequences from the CYP-REP-6 and CYP-REP-7 regions in the 29 kb CYP2D6*I allele are aligned with the 
CYP-REP-DUP region in the 42 kb allele. The alignment shows that CYP-REP-DUP is homologous to CYP-REP-6 in its 5'-end and to CYP- 
REP-7 in its 3'-end. The 2.8 kb CYP-REP units are boxed with dotted lines representing identical sequence, the extent of which is shown by 
the numbers of basepairs. 
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kb CYP-REP-7 and CYP-REP-6 units. Since the central se- 
quences of the CYP-REP units are almost identical [20], the A 1 2 3 4 5 6 7 8 
exact break points can probably not be determined. 
23.1 kb-"-~ 
3.2. PCR assays to identify alleles with duplication of the 9.4 kb . - -~  
CYP2D6 gene 6.6 kb- - -~ 
The amplification of the 9.3 kb CYP2D6-CYP2D6 inter- 4.4 kb - -~ 
genic sequence by the cyp-205/cyp-42 primer pair can be 
used to identify the 42 kb XbaI CYP2D6 duplication allele 
2,3 kb-.~ 
(Figs. 2 and 3). However, amplification of such large genomic 2.0 kb- - -~ 
DNA fragments by PCR may be more prone to failure as 
compared to shorter fragments, thereby causing false nega- B 
tives. Also, the cyp-205/cyp-42 PCR assay in some cases pro- 
duced faint, unspecific PCR products in addition to the main 
9.3 kb fragment (results not shown). As a consequence, we 23,1 kb----~ 
decided to develop more reliable PCR assays with shorter and 9,4 kb - .~  
more specific PCR products, based on our findings concerning 6.6 kb - .~  
the structure of the 42 kb XbaI allele. 4,4 kb----~ 
The sequence between the 3'-end of CYP-REP-7 and the 5'- 
end of CYP2D6 is normally not present downstream of a 2.3 kb - - .~  
CYP2D6 gene (Fig. 3). However, in the alleles with duplicated 2.0 kb- - .~  
CYP2D6 genes this unique sequence should also appear in the 
intergenic region between the two CYP2D6 genes, down- 
stream of the CYP-REP-DUP unit (Fig. 3). Moreover, the Fig. 4. PCR assays for detection of alleles with duplicated CYP2D6 
0.6 kb repeat and the 2.8 kb CYP-REP unit upstream of a genes. The primer pairs cyp-207/cyp-32 (A) and cyp-17/cyp-32 (B) 
were used to identify the 42 kb XbaI allele. DNA samples with the 
CYP2D6 gene are usually separated by a 1.6 kb DNA ele- following genotypes are shown: 42 kb/29 kb CYP2D6*2/CYP2D6*2 
ment, as in the 29 and 44 kb XbaI alleles [11]. This is not the (lane 2), 44 kb/29 kb CYP2D6*4/CYP2D6*4 (lane 3), 42 kb/13 kb 
case in the postulated CYP2D6-CYP2D6 intergenic region of CYP2D6*4/CYP2D6*5 (lane 4), 29 kb/13 kb CYP2D6*I/CYP2D6*5 
the 42 kb XbaI allele, where the 0.6 and 2.8 kb CYP-REP- (lane 5), 42 kb/29 kb CYP2D6*I/CYP2D6*I (lane 6) and 29 kb/29 
kb CYP2D6*3/CYP2D6*4 (lane 7). The DNA marker ~/HindlII is 
DUP repeats are present ogether without the 1.6 kb 'extra' shown in lane 1. 
sequence (Fig. 3). 
First, we synthesized a forward primer (cyp-207) which 
overlaps the junction between the 0.6 and 2.8 kb repeats, subjects with the 42 kb XbaI alleles only (Fig. 4A). As an 
Since this organization of the 0.6 and 2.8 kb units is usually improvement, we used a forward primer (cyp-17) which binds 
confined to the region downstream of CYP2D6, cyp-207 in the 0.6 kb repeat downstream of both CYP2D7 and 
should function as a CYP2D6-specific primer (see Fig. 3). CYP2D6. Together with the reverse cyp-32 oligonucleotide, 
The cyp-207 forward primer was used together with the cyp- this primer combination should always amplify a 5.2 kb 
32 reverse primer and yielded a specific 3.2 kb PCR product in PCR fragment from a CYP2D7-CYP2D6 intergenic region, 
Table 1 
Results of the two different PCR-based gene duplication assays with pretyped positive and negative DNA controls 
Classification of pretyped DNA samples PCR-based CYP2D6 duplication assays 
Genotype Number of samples cyp-207/cyp-32 positive cyp-17/cyp-32 positive 
Samples with 42 kb allele; n = 29 
42/42 kb CYP2D6* 1/CYP2 D6'2 n = 1 n = 1 n = 1 
42/29 kb CYP2D6* 1/CYP2 D6*l n = 3 n = 3 n = 3 
42/29 kb CYP2D6* I/CYP2 D6"2 n = 13 n = 13 n = 13 
42/29 kb CYP2D6*2/CYP2 D6'2 n = 8 n = 8 n = 8 
42/13 kb CYP2D6*2/CYP2 D6"5 n = 1 n = 1 n = 1 
42/13 kb CYP2D6*4/CYP2 D6"5 n -- 3 n = 3 n = 3 
Samples without 42 kb allele; n = 24 
44/44 kb CYP2D6*4/CYP2 D6'4 n = 1 n = 0 n = 0 
44/29 kb CYP2D6*4/CYP2 D6"4 n = 1 n = 0 n = 0 
44/16+9 kb CYP2D6*4/CYP2 D6"4 n = 1 n = 0 n = 0 
29/29 kb CYP2D6* 1/CYP2 D6* 1 n = 5 n = 0 n = 0 
29/29 kb CYP2D6* I/CYP2 D6"2 n = 6 n = 0 n = 0 
29/29 kb CYP2D6*2/CYP2 D6'2 n = 4 n = 0 n = 0 
29/29 kb CYP2D6* I/CYP2 D6"6 n = 2 n = 0 n = 0 
29/29 kb CYP2D6*3/CYP2 D6'4 n = 1 n = 0 n = 0 
29/13 kb CYP2D6* I/CYP2 D6"5 n = 1 n = 0 n = 0 
29/11 kb CYP2D6* 1/CYP2 D6* 16 n = 1 n = 0 n = 0 
n.d. CYP2D6* I/CYP2 D6"7 n = 1 n = 0 n = 0 
n.d., not determined. 
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and thus function as an internal control of the PCR reaction preting the results from PCR assays designed to detect dupli- 
(see Fig. 3). In addition, a 3.6 kb PCR fragment amplified cated CYP2D6 genes. 
from the CYP2D6-CYP2D6 region was observed in subjects 
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